FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:980-982 March 2, 2006 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: We would like to report the occurrence of reversible posterior leukoencephalopathy that we believe is directly attributable to bevacizumab (Avastin), a recombinant, humanized, monoclonal IgG1 antibody that binds and inhibits vascular endothelial growth factor (VEGF). A 59-year-old woman received seven infusions of bevacizumab at two-week intervals for the treatment of metastatic renal cancer, during which time her blood pressure remained within her usual range, at approximately 100/70 mm Hg. Eight days after the last infusion, she presented to the emergency room with severe lethargy. The physical examination was essentially normal except for a blood pressure of 168/88 . . . [Full Text of this Article]

This article has been cited by other articles:

• Novak, J. C., Lovett-Racke, A. E., Racke, M. K. (2008). Monoclonal Antibody Therapies and Neurologic Disorders. Arch Neurol 65: 1162-1165 [Abstract] [Full Text]  
• Bartynski, W.S., Tan, H.P., Boardman, J.F., Shapiro, R., Marsh, J.W. (2008). Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation. Am. J. Neuroradiol. 29: 924-930 [Abstract] [Full Text]  
• Mourad, J.-J., des Guetz, G., Debbabi, H., Levy, B. I. (2008). Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19: 927-934 [Abstract] [Full Text]  
• Maharaj, A. S.R., Walshe, T. E., Saint-Geniez, M., Venkatesha, S., Maldonado, A. E., Himes, N. C., Matharu, K. S., Karumanchi, S. A., D'Amore, P. A. (2008). VEGF and TGF-{beta} are required for the maintenance of the choroid plexus and ependyma. J. Exp. Med. 205: 491-501 [Abstract] [Full Text]  
• El Karoui, K., Le Quintrec, M., Dekeyser, E., Servais, A., Hummel, A., Fadel, F., Fakhouri, F. (2008). Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. Nephrol Dial Transplant 23: 757-763 [Full Text]  
• Bender, J. L. G., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y., Kerbel, R. S., Cooney-Qualter, E. M., Stempak, D., Chen, H. X., Nelson, M. D., Krailo, M. D., Ingle, A. M., Blaney, S. M., Kandel, J. J., Yamashiro, D. J. (2008). Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. JCO 26: 399-405 [Abstract] [Full Text]  
• Widakowich, C., de Castro, G. Jr., de Azambuja, E., Dinh, P., Awada, A. (2007). Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. The Oncologist 12: 1443-1455 [Abstract] [Full Text]  
• Rajasekhar, A., George, T. J. Jr. (2007). Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature. The Oncologist 12: 1332-1335 [Abstract] [Full Text]  
• Wong, E. T., Brem, S. (2007). Taming Glioblastoma: Targeting Angiogenesis. JCO 25: 4705-4706 [Full Text]  
• Kapiteijn, E., Brand, A., Kroep, J., Gelderblom, H. (2007). Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 18: 1745-1747 [Full Text]  
• van der Veldt, A. A. M., van den Eertwegh, A. J. M., Hoekman, K., Barkhof, F., Boven, E. (2007). Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol 18: 1747-1750 [Full Text]  
• Martin, G., Bellido, L., Cruz, J. J. (2007). Reversible Posterior Leukoencephalopathy Syndrome Induced by Sunitinib. JCO 25: 3559-3559 [Full Text]  
• Ishimori, M.L., Pressman, B.D., Wallace, D.J., Weisman, M.H. (2007). Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?. Lupus 16: 436-443 [Abstract]  
• Nagel, S., Kohrmann, M., Huttner, H. B., Storch-Hagenlocher, B., Schwab, S. (2007). Linezolid-Induced Posterior Reversible Leukoencephalopathy Syndrome. Arch Neurol 64: 746-748 [Abstract] [Full Text]  
• Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., Mayer, R. J. (2007). Adjuvant Treatment of Colorectal Cancer. CA Cancer J Clin 57: 168-185 [Abstract] [Full Text]  
• Los, M., Roodhart, J. M. L., Voest, E. E. (2007). Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. The Oncologist 12: 443-450 [Abstract] [Full Text]  
• Maitland, M. L., Ratain, M. J. (2006). Terminal ballistics of kinase inhibitors: there are no magic bullets.. ANN INTERN MED 145: 702-703 [Full Text]  
• Govindarajan, R., Adusumilli, J., Baxter, D. L., El-Khoueiry, A., Harik, S. I. (2006). Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006. JCO 24: e48-e48 [Full Text]  
• Allen, J. A., Adlakha, A., Bergethon, P. R. (2006). Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer.. Arch Neurol 63: 1475-1478 [Abstract] [Full Text]  
• Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., Sibai, B. M., Epstein, F. H., Romero, R., Thadhani, R., Karumanchi, S. A., the CPEP Study Group, (2006). Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.. NEJM 355: 992-1005 [Abstract] [Full Text]